ArticleAnnals of clinical microbiology and antimicrobials2025
Impact of sublineage diversity on intrinsic susceptibility of Beijing genotype Mycobacterium tuberculosis.
Article in Annals of clinical microbiology and antimicrobials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Genomic insights into low-level rifampicin resistance mediated by borderlineMicrobiology spectrum · 2026Article
- Machine learning-based analysis of drug resistance mutations in Mycobacterium tuberculosis.PloS one · 2026Article
- Lineage-Dependent IFN-γ Responses to Drug-Sensitive and Isoniazid-ResistantInfection and drug resistance · 2026Article
- Beyond Hotspot Mutations: Diagnostic Relevance of High Frequency, Low Frequency, and DisputedPathogens (Basel, Switzerland) · 2025Review
- Reimagining Tuberculosis Control in the Era of Genomics: The Case for Global Investment inPathogens (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Tuberculosis (TB) remains a significant global health issue, with drug-resistant TB posing a major challenge. The genetic lineage of Mycobacterium tuberculosis (Mtb) is known to influence various aspects, including drug resistance. Still, the relationship between different lineages and drug resistance levels, especially in the context of the Beijing genotype, requires further exploration. This study aimed to investigate the disparities in drug resistance among diverse lineages of Mtb. We analyzed 193 clinical isolates from drug-resistant TB patients, among them 91.2% were MDR/pre-XDR-TB. Samples were collected from patients at specific hospitals between 2014 and 2020. The isolates were subjected to smear microscopy, sputum culture, minimum inhibitory concentration (MIC) testing, and whole-genome sequencing (WGS). The MIC distributions and resistance levels of drugs like INH, AMK, RIF, EMB, and FQ were analyzed, and the association between lineages and drug resistance was determined using statistical tests. Our results showed significant differences in the MIC distributions and resistance levels of INH and AMK between lineages 2.2 and 2.3. Lineage 2.3.2 was a protective factor for high-level INH resistance, and lineage 2.3 was a protective factor for high-level AMK resistance. The L2.3.6 strain had a high proportion of high-level resistance to INH and AMK. This study provides evidence for the evolution and spread of the modern Beijing genotype of Mtb. It suggests that L2.3.6 will have the potential to become the main sublineage of tuberculosis for the spread of drug-resistant tuberculosis and the necessity of pedigree testing of drug-resistant strains in clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.